Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.
暂无分享,去创建一个
S. Gorbach | C. Wanke | D. Speigelman | T. Knox | J. Forrester | M. Silva
[1] J. Ward,et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.
[2] F. Carrat,et al. Effect of indinavir on HIV‐related wasting , 1998, AIDS.
[3] D. Spiegelman,et al. The effect of protease inhibitors on weight and body composition in HIV‐infected patients , 1998, AIDS.
[4] J. Papadimitriou,et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy , 1998, The Lancet.
[5] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[6] C. Gibert,et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[7] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[8] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.
[9] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[10] P. Singhal,et al. HIV-1 gp160 envelope protein modulates proliferation and apoptosis in mesangial cells. , 1997, Nephron.
[11] P. Kimmel,et al. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. , 1996, JAMA.
[13] R. Salata,et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. , 1996, The American journal of medicine.
[14] P. Kimmel,et al. Apoptosis in human immunodeficiency virus-associated nephropathy. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] T. Greenough,et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.
[16] E. Friedman,et al. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. , 1995, American journal of nephrology.
[17] J. Rullán,et al. HIV wasting syndrome in the United States , 1993, AIDS.
[18] John W. Ward,et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.